Lumasiran sodium

1 Cited Publications
Kundenbewertung

Based on 1 publication(s) in Google Scholar

Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit : 99.21%
  • CAS. Nr.: 1834612-06-4
  • Molecular Weight:16340 (free acid)
  • Speicherung:

    -20°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Biologische Aktivität
  • Chemical Information
  • Protokoll
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) Lumasiran sodium

More
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00